Metagenomi, Inc. (MGX)

Market Cap	236.83M
Revenue (ttm)	44.76M
Net Income (ttm)	-68.26M
Shares Out	37.47M
EPS (ttm)	-20.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	68,560
Open	6.27
Previous Close	6.17
Day's Range	6.22 - 6.69
52-Week Range	5.50 - 12.74
Beta	n/a
Analysts	Strong Buy
Price Target	21.40 (+238.61%)
Earnings Date	May 12, 2024

About MGX

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applic...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 9, 2024
• Employees: 236
• Stock Exchange: NASDAQ
• Ticker Symbol: MGX

Financial Performance

In 2023, Metagenomi's revenue was $44.76 million, an increase of 160.21% compared to the previous year's $17.20 million. Losses were -$68.26 million, 56.6% more than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for MGX stock is "Strong Buy." The 12-month stock price forecast is $21.4, which is an increase of 238.61% from the latest price.

Price Target

$21.4

(238.61% upside)

Analyst Consensus: Strong Buy